UID:
almafu_9960073812402883
Umfang:
1 online resource (xvi, 360 pages) :
,
illustrations (some color)
ISBN:
9780128020524
,
0128020520
,
9780128020258
,
0128020253
Serie:
Gale eBooks
Inhalt:
This guide surveys critical issues in therapeutic drug monitoring for non-toxicologists who want to gain greater insight into the unique requirements of special populations and learn how to avoid drug toxicity within a narrow therapeutic window.
Anmerkung:
Description based upon print version of record.
,
Front Cover; Clinical Challenges in Therapeutic Drug Monitoring; Copyright Page; Contents; List of Contributors; Preface; 1 Overview of Therapeutic Drug Monitoring; 1.1 Introduction; 1.2 Principles of TDM; 1.3 Clinical Areas in Which TDM is Routine Practice; 1.3.1 Epilepsy; 1.3.2 Organ Transplantation; 1.3.3 Cardiology (Antiarrhythmic Drugs); 1.3.4 Psychiatry; 1.3.5 Infectious Disease; 1.3.6 Oncology; 1.4 Conclusions; References; 2 Immunoassays and Issues With Interference in Therapeutic Drug Monitoring; 2.1 Introduction; 2.2 Immunoassay Platforms Used in TDM
,
2.3 Interference of Bilirubin, Hemolysis, and Lipemia2.4 Interferences in Digoxin Immunoassays; 2.4.1 DLIS Interferences in Digoxin Immunoassays; 2.4.2 Effect of Digibind and DigiFab on Digoxin Immunoassays; 2.4.3 Potassium-Sparing Diuretics and Digoxin Immunoassays; 2.4.4 Herbal Supplements and Digoxin Immunoassays; 2.5 Issues of Interferences With Immunoassays for Immunosuppressants; 2.5.1 Metabolite Interferences in Cyclosporine Immunoassays; 2.5.2 Metabolite Interferences in Tacrolimus Immunoassays; 2.5.3 Metabolite Interferences in Sirolimus and Everolimus Immunoassays
,
2.5.4 Metabolite Interferences in Mycophenolic Acid Immunoassays2.6 Interferences in Immunoassays for Anticonvulsants; 2.6.1 Interferences in Phenytoin Immunoassays; 2.6.2 Interferences in Carbamazepine Immunoassays; 2.6.3 Interferences in Phenobarbital and Valproic Acid Immunoassays; 2.6.4 Interferences in Immunoassays for Newer Anticonvulsants; 2.7 Interferences in Immunoassays for TCAs; 2.7.1 Interference of Phenothiazines and Their Metabolites in Immunoassays for TCAs; 2.7.2 Interference of Carbamazepine in Immunoassays for TCAs
,
2.7.3 Interference of Cyproheptadine and Quetiapine With Immunoassays for TCAs2.7.4 Interference of Miscellaneous Drugs With Immunoassays for TCAs; 2.8 Conclusions; References; 3 Application of Chromatography Combined With Mass Spectrometry in Therapeutic Drug Monitoring; 3.1 Introduction; 3.2 Liquid Chromatography; 3.3 Mass Spectrometry; 3.3.1 Ion Source; 3.3.2 Mass Analyzers; 3.3.2.1 Quadrupole Analyzers; 3.3.2.2 Ion Trap Analyzers; 3.3.2.3 TOF Analyzers; 3.3.3 Detectors; 3.4 Preanalytical Stage; 3.5 Application of LC-MS/MS Methods in TDM; 3.5.1 Immunosuppressants; 3.5.2 Anticonvulsants
,
3.5.3 Antidepressants3.5.4 Antifungal Drugs; 3.5.5 Others Drug Classes; 3.6 LC-MS/MS Limitations; 3.7 Conclusions; References; 4 Monitoring Free Drug Concentration: Clinical Usefulness and Analytical Challenges; 4.1 Introduction; 4.2 Drug-Protein Binding; 4.3 Drugs Requiring Free Drug Monitoring; 4.4 Conditions in Which Monitoring Free Anticonvulsants is Necessary; 4.4.1 Clinical Utility of Monitoring Free Phenytoin Concentrations; 4.4.2 Clinical Utility of Monitoring Free Valproic Acid Concentration; 4.4.3 Clinical Utility of Monitoring Free Carbamazepine Concentrations
,
4.5 Mechanisms of Elevated Free Anticonvulsant Levels in Various Pathophysiological Conditions
Sprache:
Englisch
Bookmarklink
